OncoMatch/Clinical Trials/NCT04261244
NeoRad Breast Cancer Study
Is NCT04261244 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for breast cancer.
The NEORAD trial tests whether preoperative radiotherapy results in an improved DFS and less radiation induced late effect compared to postoperative radiotherapy in higher risk breast cancer after NACT.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Grade: g1g2g3
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: endocrine therapy
Exception: sole neoadjuvant treatment
Neoadjuvant treatment solely with endocrine therapy
Cannot have received: radiation therapy
Exception: prior radiotherapy of the thorax
Prior radiotherapy of the thorax
Lab requirements
Cardiac function
No symptomatic coronary heart disease, prior heart attack, heart failure NYHA ≥II or AHA ≥C, pacemaker, and/or implanted defibrillator
Cardiac comorbidities: symptomatic coronary heart disease, prior heart attack, heart failure NYHA ≥II or AHA ≥C, pacemaker, and/or implanted defibrillator [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04261244 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior endocrine therapy, radiation therapy disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages